

## Demir, Münevver, Priv.-Doz., MD (Z01)

### Personal Data

Title	Priv.-Doz. Dr. med.
First name	Münevver
Name	Demir
Current position	Senior physician, Head of Outpatient Clinic, Department of Hepatology and Gastroenterology, Charité – Universitätsmedizin Berlin, Campus Charité Mitte (CCM) and Campus Virchow-Klinikum (CVK); permanent position
Current institution(s)/site(s), country	Department of Hepatology and Gastroenterology Charité – Universitätsmedizin Berlin, Campus Charité Mitte (CCM) and Campus Virchow-Klinikum (CVK), Augustenburger Platz 1, 13353 Berlin, Germany
Identifiers/ORCID	ORCID-ID: 0000-0002-7050-797X

### Qualifications and Career

Stages	Periods and Details
Degree programme: Medicine	2000 – 2006, Medical School, Johannes-Gutenberg Universität Mainz, Germany
Degree programme: Law	1993 – 1997, Law School, Johannes-Gutenberg Universität Mainz, Germany
Doctorate: MD thesis	10.05.2007: Supervisor: Burkhard Dick (Johannes-Gutenberg Universität Mainz), Frank Krummenauer (TU Dresden), “ <i>Phakic intraocular lenses for the surgical correction of moderate and severe myopia</i> ”, TU Dresden, Germany
Stages of academic / professional career	
Since 2019	Senior physician, Head of Outpatient Clinic Department of Hepatology and Gastroenterology, Charité – Universitätsmedizin Berlin, Campus Charité Mitte (CCM) and Campus Virchow-Klinikum (CVK), Berlin, Germany
2019	Board certification <i>Gastroenterology</i>
2017	09.10.2017: Habilitation and <i>venia legendi</i> , Mentor: Tobias Goeser, “ <i>Noninvasive Scoring Systems for Diagnosis of Fibrosis and Prediction of Hepatocellular Carcinoma Development</i> ”, University of Cologne, Germany
2014 – 2019	Senior physician, Head of Outpatient Clinic and Clinical Studies Unit, Department of Gastroenterology and Hepatology, University Hospital of Cologne, Germany
2012	Board certification <i>Internal Medicine</i>
2007 – 2014	Resident, Department of Gastroenterology and Hepatology, University Hospital of Cologne, Germany
1997 – 2000	Consultant in an NGO (“VFFG“, Wiesbaden, Germany) Key aspects of activity: Human Rights, Civil Conflict Resolution

	Strategies and Banning of Landmines (as part of the “International Campaign to Ban Landmines”)
--	--

### Engagement in the Research System

- Collaborator in the CRC 1340 “Matrix in Vision”; sub-project B07 “The Extracellular Matrix as Target for Biophysical and Molecular Imaging of Inflammation and Fibrosis of the Liver” (since 2022)
- Partner (clinical and experimental) DEEP-HCC (BMBF, since 2021)
- Working group leader national guideline “Nonalcoholic fatty liver disease” (DGVS) (2020 – 2022)
- Member of the Management Board of the German NAFLD Registry (German Liver Foundation) (since 2021)
- Spokeswoman of the working group “Fettlebererkrankung und Alkohol“ (DGVS) (since 2021)
- Deputy Spokesperson of the FOSA (Fach- und Organspezifische Arbeitsgruppe) Gastroenterologie within NAPKON (Nationale Pandemie Kohorten Netz) (since 2020)
- Reviewer for the scientific grant “Freistellungsstipendium” of the German Liver Foundation (2019 – 2021)
- Part of the reviewing board for the EASL International Liver Congress, section „NAFLD clinical“ (2018 – 2020)
- Member of the steering committee of the NAFLD clinical study group (NAFLD CSG; consortium of 28 academic liver centers) (since 2014)

### Scientific Results

#### Category A, \* contributed equally, # open access

1. Hsu CL, Lang S, **Demir M**, Fouts DE, Stärkel P, Schnabl B. Any alcohol use in NAFLD patients is associated with significant changes to the intestinal virome. **Hepatology** 2023; 77(6):2073-2083doi: 10.1097/HEP.000000000000238.
2. de Assis LVM, **Demir M**, Oster H. The role of the circadian clock in the development, progression, and treatment of non-alcoholic fatty liver disease. **Acta Physiol (Oxf)**. 2023; 237(3):e13915. doi: 10.1111/apha.13915
3. **Demir M\***, Lang S\*, Hartmann P, Duan Y, Martin A, Miyamoto Y, Bondareva M, Zhang X, Wang Y, Kasper P, Bang C, Roderburg C, Tacke F, Steffen HM, Goeser T, Kruglov A, Eckmann L, Stärkel P, Fouts DE, Schnabl B. The fecal mycobiome in non-alcoholic fatty liver disease. **J Hepatol** 2022; 76(4):788-799. doi: 10.1016/j.jhep.2021.11.029. #
4. Georg P, Astaburuaga-García R, Bonaguro L, Brumhard S, Michalick L, Lippert LJ, Kostevc T, Gäbel C, Schneider M, Streitz M, Demichev V, Gemünd I, Barone M, Tober-Lau P, Helbig ET, Hillus D, Petrov L, Stein J, Dey HP, Paclik D, Iwert C, Mülleder M, Aulakh SK, Djurdjaj S, Bülow RD, Mei HE, Schulz AR, Thiel A, Hippenstiel S, Saliba AE, Eils R, Lehmann I, Mall MA, Stricker S, Röhmel J, Corman VM, Beule D, Wyler E, Landthaler M, Obermayer B, von Stillfried S, Boor P, **Demir M**, Wesselmann H, Suttorp N, Uhrig A, Müller-Redetzky H, Nattermann J, Kuebler WM, Meisel C, Ralser M, Schultze JL, Aschenbrenner AC, Thibeault C, Kurth F, Sander LE, Blüthgen N, Sawitzki B; PA-COVID-19 Study Group. Complement activation induces excessive T cell cytotoxicity in severe COVID-19. **Cell** 2022; 1 85(3):493-512.e25. doi: 10.1016/j.cell.2021.12.040. #

5. Lang S, Martin A, Zhang X, Farowski F, Wisplinghoff H, J G T Vehreschild M, Krawczyk M, Nowag A, Kretzschmar A, Scholz C, Kasper P, Roderburg C, Mohr R, Lammert F, Tacke F, Schnabl B, Goeser T, Steffen HM, **Demir M**. Combined analysis of gut microbiota, diet and PNPLA3 polymorphism in biopsy-proven non-alcoholic fatty liver disease. **Liver Int** 2021; 41(7):1576-1591. doi: 10.1111/liv.14899. #
6. Lang S\*, **Demir M\***, Martin A, Jiang L, Zhang X, Duan Y, Gao B, Wisplinghoff H, Kasper P, Roderburg C, Tacke F, Steffen HM, Goeser T, Abraldes JG, Tu XM, Loomba R, Stärkel P, Pride D, Fouts DE, Schnabl B. Intestinal Virome Signature Associated With Severity of Nonalcoholic Fatty Liver Disease. **Gastroenterology** 2020; 159(5):1839-1852. doi: 10.1053/j.gastro.2020.07.005. #
7. Lang S, Farowski F, Martin A, Wisplinghoff H, Vehreschild MJGT, Krawczyk M, Nowag A, Kretzschmar A, Scholz C, Kasper P, Roderburg C, Lammert F, Goeser T, Steffen HM, **Demir M**. Prediction of advanced fibrosis with transient elastography is superior to gut microbiota-based approaches in non-alcoholic fatty liver disease. **Sci Rep** 2020; 10(1):9385. doi: 10.1038/s41598-020-66241-0. #
8. Lang S, Martin A, Farowski F, Wisplinghoff H, Vehreschild MJGT, Liu J, Krawczyk M, Nowag A, Kretzschmar A, Herweg J, Schnabl B, Tu XM, Lammert F, Goeser T, Tacke F, Heinzer K, Kasper P, Steffen HM, **Demir M**. High protein intake is associated with histological disease activity in patients with NAFLD. **Hepatol Commun** 2020; 4(5):681-695. doi: 10.1002/hep4.1509. #
9. Lang S,\* **Demir M,\*** Duan Y, Martin A, Schnabl B. Cytolysin-positive *Enterococcus faecalis* is not increased in patients with non-alcoholic steatohepatitis. **Liver Int** 2020; 40(4):860-865. doi: 10.1111/liv.14377. #
10. Traussnigg S, Schattenberg JM, **Demir M**, Wiegand J, Geier A, Teuber G, Hofmann WP, Kremer AE, Sprea F, Kluwe J, Petersen J, Boettler T, Rainer F, Halilbasic E, Greinwald R, Pröls M, Manns MP, Fickert P, Trauner M; Austrian/German NAFLD-norUDCA study group. Norursodeoxycholic acid versus placebo in the treatment of non-alcoholic fatty liver disease: a double-blind, randomised, placebo-controlled, phase 2 dose-finding trial. **Lancet Gastroenterol Hepatol** 2019; 4(10):781-793. doi: 10.1016/S2468-1253(19)30184-0

## Collaborators

No.	Collaboration partners	Location/Institution
1	Bernd Schnabl	San Diego, USA, University of California San Diego
2	Sofia Forslund	Berlin, Germany, Max Delbrück Center
3	Nir Friedman, Eithan Galun	Jerusalem, Israel, Hebrew University
4	Maria JGT Vehreschild	Frankfurt/Main, Germany, Universitätsklinikum Frankfurt
5	Henrik Oster	Lübeck, Germany, Universität Lübeck
6	Achim Kramer	Berlin, Germany, Charité – Universitätsmedizin Berlin
7	Christoph Roderburg, Tom Lüdde	Düsseldorf, Germany, UK Düsseldorf
8	Jochen Hampe	Dresden, Germany, TU Dresden
9	Jutta Allmendinger, Jan P. Heisig	Berlin, Germany, WZB Berlin

10	Sonja Lang, Philipp Kasper, Hans-Michael Steffen	Köln, Germany, Uniklinik Köln
----	---	-------------------------------

**Fields of Research**

No.	Fields of research
1	205-15 Medicine/ <b>Gastroenterology</b>
2	205-17 Endocrinology, Diabetology, <b>Metabolism</b>